Convergence Investment Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Convergence Investment Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.7M	Buy	23,663 +8,378	+55%	+$1.84M	0.54%	61
2026 Q1	$2.89M	Buy	15,285 +3,905	+34%	+$682K	0.47%	64
2025 Q4	$1.93M	Buy	+11,380	New	+$1.74M	0.38%	82
2025 Q2	–	Sell	-10,428	Closed	-$1.29M	–	259
2025 Q1	$1.29M	Buy	10,428 +2,043	+24%	+$267K	0.36%	93
2024 Q4	$1.03M	Buy	+8,385	New	+$988K	0.23%	143
2024 Q1	–	Sell	-1,800	Closed	-$221K	–	256
2023 Q4	$221K	Buy	1,800 +72	+4%	+$8.98K	0.12%	178
2023 Q3	$224K	Buy	+1,728	New	+$230K	0.13%	140
2016 Q3	–	Sell	-13,615	Closed	-$1.92M	–	358
2016 Q2	$1.92M	Sell	13,615 -638	-4%	-$94.1K	0.26%	139
2016 Q1	$1.86M	Buy	14,253 +4,564	+47%	+$568K	0.22%	159
2015 Q4	$1.36M	Sell	9,689 -1,670	-15%	-$231K	0.15%	211
2015 Q3	$1.51M	Buy	+11,359	New	+$1.96M	0.17%	190

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Convergence Investment Partners's JAZZ Position: Q2 2026 in Review

Convergence Investment Partners increased its Jazz Pharmaceuticals (JAZZ) stake by 55% in Q2 2026, buying an estimated $1.84M and bringing the position to 23,663 shares worth $5.7M. The position accounts for 0.54% of the portfolio, ranked #61.

Convergence Investment Partners first reported a position in JAZZ in Q3 2015 and has held it in 11 quarters since. 642 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Convergence Investment Partners held 23,663 shares of Jazz Pharmaceuticals worth $5.7M as of Q2 2026.
Convergence Investment Partners bought 8,378 Jazz Pharmaceuticals shares in Q2 2026, an estimated $1.84M.
Jazz Pharmaceuticals made up 0.54% of Convergence Investment Partners's portfolio in Q2 2026, its #61 holding.
Convergence Investment Partners first reported a position in Jazz Pharmaceuticals in Q3 2015 and has held it in 11 quarters since.
642 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Convergence Investment Partners's 13F filing for Q2 2026, filed 31 Jul 2026.